Lupin Ltd — Board/Management Information 2024

Mar 18, 2024

==> picture [79 x 93] intentionally omitted <==

March 18, 2024

 BSE Limited

Department of Corporate Services, P. J. Towers, Dalai Street, MUMBAI - 400 001.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’).

We are pleased to enclose a Press Release regarding the appointment of Mr. Christoph Funke to the newly-created position of Chief Technical Operations Officer of the Company. Mr. Funke will be based in Mumbai and oversee the technical operations of the Company globally, including manufacturing, supply chain and procurement.

The above may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2 abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cd b67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2024.03.18 11:41:19 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Appoints Christoph Funke as Chief Technical Operations Officer

Mumbai, March 18, 2024 : Global pharma major Lupin Limited (Lupin) today announced the appointment of Christoph Funke to the newly-created position of Chief Technical Operations Officer. With over 30 years of global pharmaceutical manufacturing, supply chain, and technical operations experience, Christoph brings a wealth of expertise to Lupin. He will be based in Mumbai and will oversee Lupin's Technical Operations function, integrating manufacturing, supply chain, and procurement.

Christoph’s extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science. In his leadership roles, Christoph has managed large-scale technical operations and manufacturing networks across 27 sites in 19 countries, overseeing production value exceeding USD 2 billion and leading teams of over 12,500 employees. Christoph holds an engineering degree from South Westphalia University of Applied Sciences, Germany.

Commenting on the appointment, Lupin’s CEO, Vinita Gupta, and MD, Nilesh Gupta said, “We are delighted to welcome Christoph to our executive leadership team. His impressive track record and extensive experience across manufacturing, supply chain, and technical operations make him a valuable addition as we continue to advance our mission of improving patient lives globally.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector. Please visit www.lupin.com for more information.

Follow us on:

Twitter: https://twitter.com/LupinGlobal LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

Page 1 of 2

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

For further information or queries please contact – Heena Dhedhi

Deputy General Manager - Corporate Communications Email: heenadhedhi@lupin.com

Page 2 of 2